Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Apr;92(4):1657-1661.
doi: 10.1007/s00204-018-2183-2. Epub 2018 Mar 16.

The future trajectory of adverse outcome pathways: a commentary

Fiona Sewell  1 , Nichola Gellatly  2 , Maria Beaumont  3 , Natalie Burden  2 , Richard Currie  4 , Lolke de Haan  5 , Thomas H Hutchinson  6 , Miriam Jacobs  7 , Catherine Mahony  8 , Ian Malcomber  9 , Jyotigna Mehta  10 , Graham Whale  11 , Ian Kimber  12
Affiliations
Editorial

The future trajectory of adverse outcome pathways: a commentary

Fiona Sewell et al. Arch Toxicol. 2018 Apr.

Abstract

The advent of adverse outcome pathways (AOPs) has provided a new lexicon for description of mechanistic toxicology, and a renewed enthusiasm for exploring modes of action resulting in adverse health and environmental effects. In addition, AOPs have been used successfully as a framework for the design and development of non-animal approaches to toxicity testing. Although the value of AOPs is widely recognised, there remain challenges and opportunities associated with their use in practise. The purpose of this article is to consider specifically how the future trajectory of AOPs may provide a basis for addressing some of those challenges and opportunities.

Keywords: Adverse outcome pathways (AOPs); Hazard identification; Risk assessment; Safety assessment.

PubMed Disclaimer

Conflict of interest statement

The authors did not report any conflicts of interest.

References

    1. Ankley GT, Bennett RS, Erikson RJ, Hoff DJ, Hornung MW, Johnson RD, Mount DR, Nichols JW, Russom CL, Schmieder PK, Serrano JA, TIietage JE, Villeneuve DL. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem. 2010;29:730–741. doi: 10.1002/etc.34. - DOI - PubMed
    1. Basketter DA, Alépée N, Ashikaga T, Barroso J, Gilmour N, Goebel C, Hibatallah J, Hoffmann S, Kern P, Martinozzi-Teissier S, Maxwell G, Reisinger K, Sakaguchi H, Schepky A, Tailhardat M, Templier M. Categorization of chemicals according to their relative human skin sensitizing potency. Dermatitis. 2014;25:11–21. doi: 10.1097/DER.0000000000000003. - DOI - PubMed
    1. Becker RA, Ankley GT, Edwards SW, Kennedy SW, Linkov I, Meek B, Sachana M, Segner H, Van Der Burg B, Villeneuve DL, Watanabe H, Barton-Maclaren TS. Increasing scientific confidence in adverse outcome pathways: application of tailored Bradford-Hill considerations for evaluating weight of evidence. Regul Toxicol Pharmacol. 2015;72:514–537. doi: 10.1016/j.yrtph.2015.04.004. - DOI - PubMed
    1. Bell SM, Angrish MM, Wood CE, Edwards SW. lntegrating publicly available data to generate computationally predicted adverse outcome pathways for fatty liver. Toxicol Sci. 2016;150:510–520. doi: 10.1093/toxsci/kfw017. - DOI - PubMed
    1. Burden N, Sewell F, Andersen M, Boobis A, Chipman K, Cronin M, Hutchinson T, Kimber I, Whelan M. Adverse outcome pathways can drive non-animal approaches for risk assessment. J Appl Toxicol. 2015;35:971–975. doi: 10.1002/jat.3165. - DOI - PMC - PubMed

Publication types

LinkOut - more resources